Tanezumab FDA Approval Status
Last updated by Judith Stewart, BPharm on March 27, 2020.
Tanezumab is a nerve growth factor (NGF) inhibitor in development for the treatment of patients with chronic pain due to moderate-to-severe osteoarthritis (OA) who have experienced inadequate pain relief with other analgesics.
Development timeline for tanezumab
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.